Navigation Links
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
Date:12/11/2007

dies demonstrate that Panzem(R) is a DMARD (disease modifying antirheumatic drug) that inhibits the principal symptoms of the disease, including cartilage lesions, bone resorption, cellular infiltration, and pannus formation.

Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief Medical Officer, commented, "The cross over of agents used to treat cancer into the treatment of patients with RA is well established with methotrexate being the mainstay of RA therapy. Panzem(R) is a potentially safe, orally-administered, small molecule drug candidate that could contribute to the treatment paradigm for patients with RA. Based on Panzem(R)'s demonstrated safety profile and activity in oncology patients, its mechanism of action, and its activity in preclinical RA models, we believe that Panzem(R) will be of considerable interest to clinicians as a potential treatment for RA."

James S. Burns, President & CEO, also commented, "Acceptance of the IND for Panzem(R) in RA represents the completion of a key development milestone and adds another asset to our pipeline. Our strategy moving forward will be to initiate early clinical trials internally and then seek a development partner for larger multicenter clinical trials."

About Rheumatoid Arthritis

Rheumatoid arthritis affects over 2 million American adults, of which about two-thirds of them are women. The disease, characterized by pain, stiffness, swelling, and deformity can become debilitating. Within 5 years of diagnosis, a third of patients are no longer working, and within 10 years, half of the patients have substantial functional disability. RA can shorten life expectancy by 5-10 years.

Rheumatoid arthritis (RA), one of the most common forms of arthritis, is a systemic disease characterized by inflammation of the membrane lining of the joint, which causes pain, stiffness, redness, swelling, and loss of function in the joint. The inflamed joint lining, called the synovium, releases
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York, New York (PRWEB) September 22, 2014 ... associated with the use of power morcellators ( ... LLP notes a new report detailing the continued ... warnings from federal regulators that specifically discouraged these ... physicians believe that the potential cancer risks associated ...
(Date:9/22/2014)... September 22, 2014 Pain does not need ... is a user- and reader-friendly book designed to guide the ... pain-free living. This inspirational book is written to help the ... know a way to regain a pain-free life — a ... chronic pain. , Chronic pain has become an epidemic, with ...
(Date:9/22/2014)... Medical Center, Albert Einstein College of Medicine of Yeshiva ... $300,000 grant from The Agency for Healthcare Research and ... Technology (IT) on patient safety. , This research will ... patient safety issue impacted by health IT. Upon completion ... IT leaders have data on the risk of "wrong ...
(Date:9/22/2014)... of flavonoid found in hops and beer, has been ... in young mice, but not in older animals. , ... Research by scientists from the Linus Pauling Institute ... It,s another step toward understanding, and ultimately reducing the ... mammalian species, including humans. , Flavonoids are compounds found ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Medical ... for a three-day conference to discuss brain-related diseases ... injury from concussions and neurodegenerative disorders. , ... director affiliated with a Silverado memory care community ... dedicated expertise in memory care, hosts the annual ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2Health News:AHRQ grant awarded to study the impact of health IT on patient safety at Montefiore and Einstein and Brigham and Women's Hospital 2Health News:Compound from hops aids cognitive function in young animals 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... , Who: Jordan Thomas, 2009 National Courage Award recipient, ... from, traumatic injury, Events: ... Monday, Aug. 10, 2009, 8:30 a.m. to noon, ... Medtronic Celebration of Courage Gala, ...
... work, study says , TUESDAY, Aug. 4 (HealthDay ... offices, clinics and hospitals does little to reduce ... , Their study of 6,743 women, ages 18 ... 12 family practices and three obstetrics/gynecology clinics. Of ...
... medicines such as Enbrel, Remicade , TUESDAY, Aug. 4 ... arthritis, Crohn,s disease and other inflammatory disorders must now ... patients and doctors that the medicines may boost cancer ... Drug Administration announced Tuesday. , The drugs, called ...
... of guided workplace meditation and yoga combined with six weekly ... 10 percent and improve sleep quality in sedentary office employees, ... modified version of what is known as mindfulness-based stress reduction ... in Massachusetts assist in their own healing that is now ...
... , , CHICAGO, ... of topical pain relief products, Concept Laboratories, Inc. discovered that ... pain relievers. Teaming their most high performance formulas with a ... short-lived pain relief. The MyOmega(R) pain relief line is the ...
... that consequences of osteoporosis go far beyond weak bones, , TUESDAY, ... have nearly a 25 percent chance of dying in the next ... rate for those who have a spinal fracture is 16 percent, ... issue of the Canadian Medical Association Journal . , The ...
Cached Medicine News:Health News:National Courage Award Winner Jordan Thomas to Participate in PGA Adapted Youth Golf Clinic 2Health News:Screening May Not Lessen Domestic Violence 2Health News:Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA 2Health News:Certain Arthritis, Crohn's Drugs May Raise Kids' Cancer Risk: FDA 3Health News:Pilot study: Workplace yoga and meditation can lower feelings of stress 2Health News:Pilot study: Workplace yoga and meditation can lower feelings of stress 3Health News:Pilot study: Workplace yoga and meditation can lower feelings of stress 4Health News:Nanotechnology Transforms Pain Relief 2Health News:Nanotechnology Transforms Pain Relief 3Health News:Nanotechnology Transforms Pain Relief 4Health News:With a Broken Hip Comes Higher Risk for Dying 2Health News:With a Broken Hip Comes Higher Risk for Dying 3
(Date:9/22/2014)... , Sept. 22, 2014  Sutro Biopharma today ... as one of 2014,s Fierce 15 biotechnology companies, ... biotechnology companies in the industry.  "Sutro ... of backers as well as industry partners for what ... conjugates and bispecifics," says John Carroll , editor ...
(Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... Chinese Diclofenac Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
Breaking Medicine Technology:FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2
... Boston Scientific Corporation (NYSE: BSX ) today announced ... the "Donald S. Baim, M.D., ,75 Scholarship Fund" for Yale ... interventional cardiology pioneer and Yale School of Medicine graduate who ... 2006 until 2009, when he died unexpectedly. ...
... DEERFIELD, Ill., Feb. 15, 2011 Takeda Pharmaceuticals ... Company Limited, today announced that its Pharmaceutical Development ... (NYSE: CVD ) and Quintiles, two ... Under terms of the agreements, Covance ...
Cached Medicine Technology:Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 2Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 3Boston Scientific Establishes Endowment for Donald S. Baim, M.D., Scholarship at Yale School of Medicine 4Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: